vascular
leak
key
driver
organ
injuri
diseas
acut
respiratori
distress
syndrom
caus
virus
includ
strategi
reduc
enhanc
permeabl
vascular
inflamm
promis
therapeut
target
activ
tyrosin
kinas
signal
pathway
import
regul
vascular
quiescenc
describ
design
construct
new
solubl
mimet
potent
activ
endotheli
vitro
vivo
use
chimer
fusion
strategi
replac
extracellular
matrix
ecm
bind
oligomer
domain
heptamer
scaffold
deriv
cterminu
serum
complement
protein
protein
refer
new
fusion
protein
biolog
form
stabl
heptam
induc
phosphoryl
cultur
cell
lung
follow
iv
inject
mice
inject
amelior
vegfand
lipopolysaccharideinduc
vascular
leakag
keep
known
function
maintain
quiescent
vascular
stabil
therefor
promis
candid
treatment
inflammatori
endotheli
dysfunct
authorfund
right
reserv
reus
allow
without
permiss
sinc
first
clinic
use
vegf
antagonist
cancer
vascular
eye
diseas
decad
ago
rapid
develop
new
drug
target
pathway
pathway
major
ligand
strong
agonist
act
contextdepend
antagonist
one
key
distinct
two
ligand
selfclust
higher
order
oligom
critic
induc
activ
secret
varieti
perivascular
cell
type
act
cognat
receptor
cell
surfac
endothelium
regul
junction
stabil
protect
vascular
leakag
local
transient
increas
blood
vessel
permeabl
occur
inflamm
ischemia
tumorrel
neoangiogenesi
reduct
vascular
leak
link
better
patient
outcom
sepsi
ard
condit
therapeut
target
pathway
attempt
mani
group
current
number
investig
drug
test
aim
activ
activ
includ
recombin
protein
fibrinogenlik
domain
fld
fuse
either
fc
coiledcoil
domain
ccd
rat
cartilag
oligomer
matrix
protein
comp
respect
small
molecul
inhibit
activ
phosphatas
veptp
abl
potent
activ
ligand
independ
manner
addit
therapeut
antibodi
develop
antagon
inflam
vasculatur
includ
neutral
antibodi
trebananib
nesvacumab
well
bispecif
antibodi
recent
antibodi
abtaa
shown
trigger
cluster
convert
agonist
date
angtietarget
drug
test
patient
cancer
well
patient
retin
vascular
diseas
wet
agerel
macular
degener
wamd
diabet
macular
oedema
dmo
clinic
set
vascular
leak
believ
play
pathogen
role
mode
deliveri
import
consider
angpttietarget
therapi
addit
bind
cellcel
contact
stabil
endotheli
junction
affin
bind
varieti
extracellular
matric
ecm
respons
anchor
endotheli
cellecm
attach
action
endogen
larg
restrict
mediat
pericyteendothelium
commun
order
creat
system
therapi
activ
need
consid
overcom
sticki
affin
rapidli
bind
ecm
becom
immobil
overcom
issu
ecm
bind
replac
coiledcoil
domain
linker
sequenc
amino
acid
segment
deriv
serum
complement
natur
fold
heptaval
scaffold
allow
recombin
protein
circul
freeli
maintain
potent
activ
abil
contrast
nativ
compris
nterminu
superclust
domain
scd
coiledcoil
domain
ccod
follow
fibrinogenlik
domain
fld
two
recombin
fusion
fld
amino
acid
cterminu
domain
amino
acid
construct
nto
cterminu
order
produc
use
cho
cell
product
system
method
expect
segment
form
sevenunit
stalk
secur
intermolecular
disulfid
bridg
top
cluster
seven
fld
stabl
molecular
complex
bottom
keep
appear
high
order
oligom
kda
size
nonreduc
sdspage
contrast
reduc
monomer
counterpart
kda
electron
microscopi
confirm
format
heptam
storag
stabil
biolog
tend
problemat
express
test
sever
variant
fusion
construct
result
show
regardless
ntoc
domain
order
tag
locat
variant
form
stabl
complex
supplementari
figur
could
safe
store
physiolog
buffer
condit
format
protein
aggreg
addit
specif
test
freezethaw
cycl
quantiti
qualiti
declin
protein
complex
determin
uplcsec
analysi
supplementari
figur
determin
direct
bind
seri
coimmunoprecipit
assay
show
bind
expect
ad
purifi
cultur
medium
human
umbil
vein
cell
huvec
observ
activ
measur
phosphoakt
use
human
embryon
kidney
cell
system
stabli
express
fulllength
show
induc
phosphoryl
dosedepend
manner
furthermor
immunofluoresc
studi
show
dynam
redistribut
pattern
surfac
huvec
follow
stimul
resembl
effect
natur
caus
coalesc
small
puncta
also
migrat
toward
cell
peripheri
suggest
adequ
signal
achiev
expect
confluent
huvec
cultur
form
continu
cellcel
junction
wherea
treatment
cell
either
lp
vegf
caus
disrupt
junction
area
meanwhil
present
junction
integr
maintain
spite
lp
vegf
treatment
consist
function
maintain
endotheli
quiescenc
stabil
littl
bodi
weight
purifi
inject
intraven
mice
elev
level
detect
lung
strong
signal
persist
least
hour
follow
bolu
inject
residu
activ
remain
detect
hour
later
intraperiton
inject
young
mice
also
result
activ
lung
sinc
vascular
therapi
broad
indic
ocular
diseas
also
test
pharmacokinet
compound
follow
intraocular
inject
rabbit
follow
singl
intravitr
inject
presenc
drug
detect
last
least
day
aqueou
day
vitreou
demonstr
excel
vivo
stabil
biolog
next
perform
seri
pharmacolog
test
use
mous
model
evalu
effect
drug
protect
mice
patholog
vascular
leakag
use
evan
blue
tracer
examin
vivo
efficaci
prevent
vegfinduc
microvascular
leakag
skin
experi
demonstr
either
administr
local
intraderm
inject
system
iv
inject
markedli
reduc
leakag
locat
intraderm
vegf
inject
furthermor
chemicalinduc
vascular
leakag
model
use
mustard
oil
level
evan
blue
leakag
also
significantli
lower
treatment
group
model
lung
injuri
lead
ard
sepsi
adapt
lipopolysaccharideinhal
protocol
induc
lung
edema
mice
divid
group
without
treat
iv
inject
expect
mice
receiv
two
dose
treatment
partial
protect
lipopolysaccharideinduc
lung
injuri
measur
vascular
leakag
meanwhil
toler
test
repeat
dose
inject
mice
daili
day
overt
advers
effect
shown
sought
develop
biobett
analog
pharmaceut
candid
use
ration
recombin
engin
design
overal
strategi
overcom
key
therapeut
limit
nativ
nonspecif
sequestr
ecm
easi
aggreg
still
preserv
high
degre
oligomer
chose
protein
scaffold
segment
abund
serum
complement
protein
complex
character
seven
function
polypeptid
chain
extend
intertwin
scaffold
construct
sever
variant
fusion
protein
show
form
stabl
heptam
express
cho
cell
intraderm
intraven
intraperiton
intravitr
inject
mice
rabbit
show
longlast
activ
protect
varieti
type
inflammatori
vascular
leak
recent
year
major
advanc
drug
develop
specif
target
angptti
pathway
strategi
includ
mimet
neutral
antibodi
bispecif
doubletarget
antiangiogen
antibodi
affin
trap
link
vegf
similarli
small
molecul
inhibitor
veptp
catalyt
activ
among
other
except
kinas
inhibitor
therapi
design
elev
activ
function
promot
vascular
stabil
reduc
vascular
respons
inflammatori
signal
theoret
activ
counteract
vegfinduc
neovascular
inflammatori
leakag
characterist
mani
human
diseas
mani
clinic
studi
demonstr
associ
elev
express
circul
poor
clinic
outcom
diseas
character
vascular
leakag
tissu
damag
remain
unclear
elev
level
antagon
activ
inflamm
causal
agonist
mimet
treatment
predict
amelior
vascular
destabil
occur
sever
infecti
condit
pneumonia
flu
coronaviru
inde
sever
clinic
studi
confirm
ratio
circul
predict
patient
outcom
prior
studi
therapi
design
tri
nterminu
domain
analog
remov
replac
less
sticki
structur
strategi
includ
contain
dimer
fc
domain
tandem
arrang
fld
achiev
multimer
second
strategi
fuse
fld
short
coiledcoil
domain
cartilag
oligomer
matrix
protein
comp
gener
pentamer
complex
super
ligand
activ
howev
improv
solubl
nativ
coiledcoiltocoiledcoil
interact
tend
broad
interact
prefer
among
differ
coiledcoil
domain
propens
trigger
protein
aggreg
product
may
also
retain
ecm
inject
due
gener
affin
coiledcoil
domain
toward
tissu
coiledcoil
protein
abundantli
found
ecm
hypothes
select
scaffold
better
serumcompat
may
solv
multipl
problem
ecmsequestr
degrad
system
circul
protein
aggreg
product
storag
possibl
antigen
besid
form
heptamer
scaffold
select
complex
use
construct
carri
immunogen
parent
protein
henc
structur
resembl
nativ
heptamer
complex
abl
function
potent
ligand
via
highli
cluster
fld
furthermor
well
toler
mice
daili
inject
two
week
sinc
fusion
construct
use
human
protein
sequenc
perform
longterm
inject
studi
beyond
day
due
concern
develop
crossspeci
neutral
antibodi
summari
design
construct
new
fusion
new
candid
mimet
therapi
fusion
display
remark
stabil
high
multimer
potent
activ
suitabl
system
administr
furthermor
studi
valid
gener
strategi
use
scaffold
drug
design
high
degre
oligomer
state
desir
construct
cdna
refer
chimer
fusion
cterminu
fld
cterminu
segment
ntocterminu
order
respect
either
direct
cterminu
segment
deriv
human
protein
access
cterminu
fld
segment
deriv
human
sequenc
access
amino
acid
dna
sequenc
encod
synthes
integr
dna
technolog
clone
vector
polyhistidin
tag
includ
ctermini
sequenc
product
recombin
perform
clonal
express
system
describ
previous
briefli
construct
express
vector
transfect
cell
select
dmem
medium
supplement
individu
coloni
visibl
microscop
individu
coloni
select
expand
separ
well
express
recombin
protein
measur
elisa
use
antihi
tag
monoclon
antibodi
invitrogen
captur
biotinyl
antibodi
detect
r
system
clone
show
highest
titer
recombin
protein
select
protein
product
nunc
cellfactori
system
thermofish
use
serumfre
cultur
medium
centrifug
clear
cell
debri
follow
concentr
buffer
exchang
imac
bind
buffer
use
vivaflow
system
sartoriu
result
protein
solut
purifi
histrap
column
ge
healthcar
buffer
exchang
dpb
use
desalt
column
thermo
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
scaleup
product
variant
altern
cho
express
system
use
describ
previous
molecular
size
protein
complex
determin
gel
electrophoresi
western
blot
sizeexclus
chromatographi
either
reduc
nonreduc
condit
molecular
size
monomer
heptamer
form
determin
sdspage
western
blot
respect
antihi
tag
monoclon
antibodi
invitrogen
use
western
blot
analysi
tem
analysi
protein
complex
conduct
follow
standard
neg
stain
protocol
brief
purifi
dilut
dpb
concentr
ugml
ul
droplet
appli
glowdischarg
carbonco
copper
grid
allow
sit
minut
grid
wash
dip
two
separ
drop
water
follow
two
drop
uranyl
acet
electron
microscopi
scienc
grid
examin
northwestern
electron
probe
instrument
center
epic
use
hitachi
biolog
stem
microscop
ectodomain
amino
acid
fusion
bind
measur
coimmunoprecipit
assay
ng
recombin
nativ
protein
r
system
mix
ng
tag
r
system
tbst
buffer
hour
ul
protein
g
agaros
bead
sigma
ad
incub
anoth
hour
bead
collect
centrifug
wash
five
time
tbst
immunoprecipit
protein
elut
reduc
sdspage
sampl
buffer
analyz
western
blot
use
antihi
tag
antibodi
two
experiment
system
use
evalu
cell
signal
respons
treatment
human
umbil
vein
cell
huvec
atcc
stabl
express
full
length
cterminu
flag
tag
dose
time
respons
huvec
cell
conduct
ad
purifi
protein
directli
cultur
medium
indic
period
time
follow
cell
lysi
immunoblot
phosphoakt
cell
studi
conduct
stimul
cell
follow
antiflag
immunoprecipit
ip
stabli
express
cell
surfac
ip
subject
immunoblot
analysi
measur
antiphosphotyrosin
antibodi
blot
platinum
millipor
immunofluoresc
stain
huvec
respons
conduct
describ
previous
brief
huvec
transfect
electropor
fulllength
fuse
cterminu
flag
tag
two
day
transfect
purifi
protein
buffer
control
ad
cultur
medium
follow
incub
period
min
cell
fix
stain
antiflag
antibodi
sigma
detect
investig
integr
cell
junction
huvec
treat
lp
ngml
vegf
ngml
min
presenc
vehicl
ngml
cell
fix
stain
antivecadherin
antibodi
millipor
vivo
activ
assay
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
vehicl
intraven
inject
week
old
femal
balbc
mice
intraperiton
inject
balbc
neonat
specifi
time
mice
sacrif
lung
collect
lyse
ripa
buffer
supplement
proteinasephosphatas
inhibitor
cocktail
mg
tissu
per
ml
lysi
buffer
protein
immunoprecipit
lysat
use
antibodi
millipor
protein
agsepharos
phosphoryl
level
precipit
assess
antiphosphotyrosin
antibodi
describ
rabbit
eye
pharmacokinet
studi
new
zealand
white
nzw
rabbit
use
assess
intraocular
pharmacokinet
procedur
describ
previous
briefli
proparacain
hydrochlorid
alcain
alcon
administ
eye
minim
discomfort
approxim
protein
dpb
solut
inject
intravitr
one
eye
use
seri
hamilton
syring
gaug
needl
contralater
eye
inject
buffer
control
aqueou
humor
collect
daili
preinject
sampl
day
seven
consecut
day
level
measur
elisa
describ
seventh
day
anim
sacrif
vitreou
humor
sampl
eye
collect
detect
level
elisa
mile
assay
vegf
induc
skin
vascular
leakag
perform
describ
previous
briefli
week
old
femal
balbc
mice
ip
inject
histamin
inhibitor
pyrilamin
ulg
bodi
weight
follow
tail
vein
inject
evan
blue
dye
pb
min
mice
anesthet
ketaminexylazin
cocktail
vehicl
vegf
r
system
either
presenc
absenc
ng
intraderm
inject
differ
site
mous
flank
mice
sacrif
min
intraderm
inject
leakag
evan
blue
photograph
quantifi
deioniz
formamid
extract
follow
spectrophotomet
measur
nm
investig
whether
pretreat
prevent
vegf
induc
skin
vascular
leakag
two
group
week
old
femal
balbc
mice
receiv
tail
vein
inject
either
evan
blue
evan
blue
solut
ugg
bodi
weight
min
vegf
differ
dose
intraderm
inject
differ
site
mous
flank
mice
sacrif
min
intraderm
inject
leak
evan
blue
site
photograph
mustard
oil
induc
vascular
leakag
model
week
old
femal
balbc
mice
iv
inject
either
vehicl
protein
min
mice
receiv
iv
inject
evan
blue
dye
dpb
ul
mustard
oil
allylisoyhiocyan
dilut
miner
oil
sigma
miner
oil
control
appli
dorsal
ventral
surfac
ear
min
ear
collect
leak
evan
blue
quantifi
describ
group
mice
receiv
intranas
inhal
ul
lp
iv
inject
ug
g
bw
pb
lung
permeabl
assess
iv
inject
ul
evan
blue
pb
one
hour
evan
blue
administr
mice
euthan
lung
tissu
collect
leakag
evan
blue
quantifi
describ
figur
construct
heptamer
nativ
compris
nto
cterminu
order
superclust
domain
scd
coiledcoil
domain
ccod
fibrinogenlik
domain
bind
top
ccod
mediat
ccodccod
interact
molecul
middl
linker
segment
fld
also
bind
ecm
scd
cluster
higher
degre
complex
bottom
b
cterminu
natur
fold
barrel
structur
interlink
disulfid
bridg
red
neighbor
subunit
total
seven
eight
subunit
complet
barrel
structur
top
display
seven
fld
arrang
reminisc
nativ
bottom
compar
c
express
transfect
encod
plasmid
cell
purifi
cultur
media
protein
detect
monom
sdspage
reduc
condit
heptam
nonreduc
nr
condit
electron
micrograph
em
imag
show
cluster
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
figur
vitro
activ
toward
use
ectodomain
form
fc
fusion
direct
interact
recombin
nativ
sequenc
test
coimmunoprecipit
assay
follow
antifc
immunoprecipit
presenc
variant
detect
antihi
tag
blot
b
altern
ntoc
domain
arrang
could
activ
huvec
cell
measur
akt
phosphoryl
pakt
c
use
cell
line
stabli
transfect
full
length
treatment
cell
elev
phosphotyrosin
ptyr
level
measur
immunoprecipit
antiflag
antibodi
follow
immunoblot
antiptyr
antibodi
huvec
transfect
full
length
subject
vehicl
control
treatment
subcellular
distribut
pattern
shown
antiflag
immunofluoresc
stain
repres
singl
cell
imag
shown
group
e
confluent
huvec
treat
lp
lp
togeth
vegf
vegf
togeth
min
follow
fixat
cell
stain
vecadherin
red
mark
cell
junction
lp
vegf
caus
partial
disrupt
junction
point
arrow
cotreat
cell
maintain
integr
junction
scale
bar
follow
immunoprecipit
level
measur
immunoblot
antiptyr
antibodi
b
c
time
cours
studi
respons
neonat
mice
inject
vehicl
control
intraperiton
ip
administr
tissu
harvest
four
hour
later
measur
level
e
three
rabbit
subject
singl
dose
intravitr
inject
aqueou
humor
collect
daili
preinject
sampl
day
seven
day
level
measur
elisa
use
antihi
captur
antibodi
detect
antibodi
valu
f
seventh
day
anim
sacrif
vitreou
sampl
collect
detect
level
asterisk
p
p
b
c
instead
local
inject
biolog
administr
prophylact
via
iv
min
prior
leakag
induct
either
vegf
b
mustard
oil
c
asterisk
p
mous
model
lipopolysaccharid
lp
induc
lung
injuri
time
cours
lp
inhal
inh
inject
evan
blue
inject
follow
indic
top
panel
one
hour
evan
blue
inject
lung
harvest
measur
leakag
imag
quantif
asterisk
p
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
